Martingale Asset Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Martingale Asset Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$209K	Buy	+16,552	New	+$222K	0.01%	774
2023 Q3	–	Sell	-21,865	Closed	-$468K	–	799
2023 Q2	$468K	Buy	21,865 +501	+2%	+$14.8K	0.01%	628
2023 Q1	$864K	Buy	21,364 +501	+2%	+$23.9K	0.02%	481
2022 Q4	$971K	Buy	20,863 +3,706	+22%	+$169K	0.02%	463
2022 Q3	$891K	Buy	17,157 +1,451	+9%	+$84.8K	0.02%	475
2022 Q2	$743K	Buy	15,706 +300	+2%	+$16.3K	0.01%	546
2022 Q1	$1.1M	Buy	15,406 +100	+0.7%	+$6.51K	0.02%	459
2021 Q4	$1.15M	Sell	15,306 -15,152	-50%	-$1.19M	0.01%	457
2021 Q3	$1.73M	Buy	30,458 +11,050	+57%	+$546K	0.02%	351
2021 Q2	$855K	Hold	19,408	–	–	0.01%	442
2021 Q1	$958K	Buy	19,408 +1,399	+8%	+$69.8K	0.01%	437
2020 Q4	$759K	Sell	18,009 -22,899	-56%	-$1.01M	0.01%	517
2020 Q3	$1.87M	Buy	40,908 +31,206	+322%	+$1.51M	0.02%	440
2020 Q2	$488K	Buy	+9,702	New	+$502K	0.01%	881

Other funds holding ENTA

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

SSC

Spruce Street Capital New York $416M AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Martingale Asset Management's ENTA Position: Q1 2026 in Review

Martingale Asset Management opened a new position in Enanta Pharmaceuticals (ENTA) in Q1 2026: 16,552 shares worth $209K. The stake represents 0.01% of the portfolio and ranks #774 among its holdings. This is a return to the name: Martingale Asset Management previously reported a position in ENTA as recently as Q2 2023.

Martingale Asset Management first reported a position in ENTA in Q2 2020 and has held it in 14 quarters since. The position peaked at $1.87M in Q3 2020. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

Martingale Asset Management held 16,552 shares of Enanta Pharmaceuticals worth $209K as of Q1 2026.
Enanta Pharmaceuticals was a new Martingale Asset Management position in Q1 2026.
Enanta Pharmaceuticals made up 0.01% of Martingale Asset Management's portfolio in Q1 2026, its #774 holding.
Martingale Asset Management first reported a position in Enanta Pharmaceuticals in Q2 2020 and has held it in 14 quarters since.
Martingale Asset Management's Enanta Pharmaceuticals position peaked at $1.87M in Q3 2020.
132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Martingale Asset Management's 13F filing for Q1 2026, filed 13 May 2026.